Although PD-L1 is a useful biomarker in non-oncogene-addicted tumours, it fails to predict benefit in patients harbouring EGFR, ALK or ROS1 genomic alterations, even when PD-L1 is strongly positive46,47. Here, CD274 is linked to neoplasm.